Gene and Cell Therapy Group
- Research team
- Public Engagement
- Our research programme
- Frequently asked questions
- Jobs and Studentships
- Support our research
- Contact Us
- Find Us
- Our research in the media
- Athena Vision Website
EyeTherapy Blog News
Athena Vision launches; developing gene therapies for devastating eye diseases
Tue, 24 Nov 2015 11:53:39 +0000
Athena Vision is focused on developing gene therapies for eye diseases based on research conducted at UCL Today sees the launch of Athena Vision Limited a biopharmaceutical company focused on the development of gene therapies to treat a range of devastating eye diseases causing blindness. Launched by UCL Business PLC, the wholly-owned technology transfer company of UCL, […]Read more...
Registration for Retina Day 2015 Now Open!
Wed, 10 Jun 2015 11:37:25 +0000
It’s that time once agin for our annual research day for patients and the public. Retina Day 2015 is a free, one day event is organised by the Gene and Cell Therapy Group, UCL Institute of Ophthalmology and NIHR Moorfields Biomedical Research Centre. Come along to: * Hear about some of the latest innovations in research […]Read more...
UCL RPE65 Gene Therapy Trial Shows Benefit in People with Leber Congenital Amaurosis Type 2 for up to Three Years After Treatment
Tue, 05 May 2015 14:44:39 +0000
We are delighted to be able to announce that yesterday, Monday 4th May, the long-term results of our RPE65 gene therapy trial for Leber Congenital Amaurosis Type 2 (LCA2) were published in the prestigious New England Journal of Medicine. Begun in 2007, this was the world’s first-in-human trial of gene therapy to treat an inherited […]Read more...
Our research programme
Clinical trials of gene and cell therapy for sight loss
We are currently conducting two ground-breaking clinical trials:
The world's first gene therapy trial in the eye, testing the safety and efficacy of delivering the RPE65 gene to the eyes of patients with Leber congenital amaurosis.
Europe's first trial testing the safety of transplanting stem cell-derived retinal cells into the eyes of patients with Stargardt disease.
A pipeline of gene and cell therapies for sight loss
Gene and cell therapies for inherited sight loss
We are developing a pipeline of potential therapies for which we have
established proof-of-concept, showing that gene therapy and the
transplantation of retinal cells derived from stem cells are effective
restoring vision in small and large animal models of inherited retinal
Gene and cell therapies for age-related macular degeneration (AMD)
We are investigating novel treatments for AMD that build on our understanding of the causes of sight loss in this complex disease. Our programme of laboratory research into AMD covers the mechanisms of sight loss and the development of both gene and cell therapy.
Gene therapy for diabetic eye disease
Diabetic eye disease, including diabetic retinopathy and maculopathy, is the leading cause of vision loss amongst those with diabetes.
We have used several well-established animal models of disease to further our understanding of factors that contribute to vision loss in these diseases, with a view to identifying drug targets and ways to intervene using gene and cell therapy.
Gene therapy for uveitis
We have established proof-of-concept that the delivery of genes encoding anti-inflammatory proteins can reduce damage to the retina in models of uveitis, and are developing new and more effective ways of treating this common cause of sight loss.
Gene therapy for corneal disease
We are developing ways of improving the quality of corneas used for transplant, and reducing the chances of immune rejection, using gene therapy.
Page last modified on 11 sep 12 14:23